SOL-R enrollment complete; shareholders approve 8.75M share increase and CEO award

OCULAR THERAPEUTIX, INC

SOL-R Phase 3 trial for AXPAXLI (wet AMD) completed enrollment on May 31, 2025; target randomization of at least 555 subjects.
Stockholders approved Amendment No. 4 increasing 2021 Stock Incentive Plan shares by 8,750,000 shares.
Stockholders approved Amended and Restated ESPP increasing shares by 2,000,000 and removing evergreen provision.
CEO Dr. Dugel granted performance stock option award for up to 2,750,000 shares at $7.44/share, vesting on stock price hurdles.
Certificate of Amendment filed to provide officer exculpation (limitation of liability) per Delaware law.

item 5.02 item 5.03 item 5.07 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

OCULAR THERAPEUTIX, INC: Amended restated certificate of incorporation to provide for officer exculpation (effective 2025-06-11).

Change: charter amendment
Effective: 2025-06-11

Exact text from the filing

At the 2025 Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), to update its existing director exculpation provision to include the exculpation of certain of the Company’s senior corporate officers, subject to specified limitations. The Company filed the Certificate of Amendment, which was effective upon filing, with the Secretary of State of the State of Delaware on June 11, 2025.

View on SEC.gov

Browse all governance changes →

OCULAR THERAPEUTIX, INC filing history →

Source: SEC EDGAR

accession 0001104659-25-058525

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.